Neoadjuvant radiochemotherapy and perioperative chemotherapy do not represent a standard at the same priority level for esophageal adenocarcinomas (with regard to ‘Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up’)-Reference-Cited by-同舟云学术

Neoadjuvant radiochemotherapy and perioperative chemotherapy do not represent a standard at the same priority level for esophageal adenocarcinomas (with regard to ‘Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up’)

Published:2023-06 Issue:6 Volume:34 Page:553-554
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cellini F.,Manfrida S.,Gambacorta M.A.,Valentini V.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference7 articles.

1. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Obermannová;Ann Oncol,2022

2. Preoperative chemoradiotherapy for esophageal or junctional cancer;van Hagen;N Engl J Med,2012

3. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer;Cunningham;N Engl J Med,2006

4. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

5. Role of neoadjuvant radiochemotherapy for esophageal cancers over pre/peri-operative chemotherapy in the era of COVID-19 and beyond;Cellini;Radiother Oncol,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lymphocyte to Monocyte Ratio Is an Independent Prognostic Factor in Patients With Esophageal Cancer Who Receive Curative Treatment;Anticancer Research;2023-12-30